Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer

Background: Osimertinib is a 3rd-generation tyrosine kinase inhibitor (TKI) that blocks the epidermal growth factor receptor (EGFR) in non-small lung cancer (NSCLC) and has dramatically improved outcomes for patients with EGFR mutations. While gastrointestinal complications such as diarrhea have bee...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Oncol
Autors principals: Patil, Tejas, Pacheco, Jose M., Dimou, Anastasios, Purcell, William T., Rossi, Candice, Bunn, Paul A., Doebele, Robert C., Camidge, D. Ross, Ferrigno, Lisa
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7174901/
https://ncbi.nlm.nih.gov/pubmed/32351892
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00510
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars